Melasma 2025 Update: Newer Etiologies, Newer Therapies, and Procedural Approaches
A paradigm shift in the understanding of melasma is changing the way dermatology clinicians approach the condition. Next Steps in Derm, in partnership with the ODAC Dermatology Conference, interviewed Dr. Mukta Sachdev, head of the department of dermatology at Manipal Hospital, Bangalore, India. Watch as Dr. Sachdev shares why photoprotection, barrier function, and pollution are some of the factor …
A paradigm shift in the understanding of melasma is changing the way dermatology clinicians approach the condition. Next Steps in Derm, in partnership with the ODAC Dermatology Conference, interviewed Dr. Mukta Sachdev, head of the department of dermatology at Manipal Hospital, Bangalore, India. Watch as Dr. Sachdev shares why photoprotection, barrier function, and pollution are some of the factor … Continue reading "Melasma 2025 Update: Newer Etiologies, Newer Therapies, and Procedural Approaches"
Secukinumab is a recombinant human monoclonal immunoglobulin IgG1κ antibody that selectively targets interleukin-17A (IL-17A), a key effector cytokine in the Th17 pathway implicated in the pathogenesis of psoriasis. With its high target specificity, rapid onset, sustained efficacy, and favorable safety profile, secukinumab has become a mainstay in the treatment of psoriasis and other inflammatory … 
While the importance of wearing sunscreen is often emphasized, rarely do we stop to consider how sunscreen works and why it is effective. A thorough understanding of these details is essential for dermatologists and trainees alike to feel confident navigating conversations with patients about sunscreen formulations, efficacy, and safety. At the inaugural Lab to Label Conference, Dr. Candrice Heath … 
The psoriasis research pipeline is rich with new medications as well as new ways to use existing therapies, according to Dr. Anthony Fernandez, director of medical and inpatient dermatology at the Cleveland Clinic. Next Steps in Derm, in partnership with the ODAC Dermatology Conference, interviewed Dr. Fernandez, who outlined three therapeutic areas he’s most excited about in the treatment of p … 
Leslie Rank, PhD, Global Product Development Lead of Facial Treatment Products, and Rachel Bechtel, Senior Scientist on the Facial Cleansing Product & Process Innovation Team at Kenvue, spoke to dermatology residents at The George Washington University’s first Lab to Label Conference, about the formulation of popular products including dark spot actives, vitamin A derivatives, and cleansers. …